Previous studies have shown that EZH2 is overexpressed in many solid cancers, including breast cancer (6), lung cancer (7), ovarian cancer (8) and colon cancer (9), and is linked to cancer proliferation and aggressiveness. Here, EZH2 is linked to breast cancer.